Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety, tolerability, and effectiveness of the
investigational drug nivolumab (Opdivo™) in combination with high dose radiation.
Investigators also want to see if these study drugs help to delay the progression of prostate
cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute